IIQ Stock Overview
Engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
INOVIQ Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.48 |
| 52 Week High | AU$0.82 |
| 52 Week Low | AU$0.43 |
| Beta | 2.04 |
| 11 Month Change | -3.03% |
| 3 Month Change | -24.41% |
| 1 Year Change | -24.41% |
| 33 Year Change | -54.93% |
| 5 Year Change | -50.00% |
| Change since IPO | -27.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| IIQ | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | 7.9% | 0.09% | 1.4% |
| 1Y | -24.4% | 2.4% | 17.7% |
Return vs Industry: IIQ underperformed the Australian Healthcare industry which returned -1.8% over the past year.
Return vs Market: IIQ underperformed the Australian Market which returned 16.9% over the past year.
Price Volatility
| IIQ volatility | |
|---|---|
| IIQ Average Weekly Movement | 6.9% |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: IIQ has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IIQ's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Leearne Hinch | www.inoviq.com |
INOVIQ Ltd engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. Its cancer diagnostic pipeline includes internal and partnered diagnostic tests for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases.
INOVIQ Ltd Fundamentals Summary
| IIQ fundamental statistics | |
|---|---|
| Market cap | AU$52.42m |
| Earnings (TTM) | -AU$6.55m |
| Revenue (TTM) | AU$1.56m |
33.6x
P/S Ratio-8.0x
P/E RatioIs IIQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IIQ income statement (TTM) | |
|---|---|
| Revenue | AU$1.56m |
| Cost of Revenue | AU$2.78m |
| Gross Profit | -AU$1.22m |
| Other Expenses | AU$5.34m |
| Earnings | -AU$6.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | -78.07% |
| Net Profit Margin | -419.73% |
| Debt/Equity Ratio | 0% |
How did IIQ perform over the long term?
See historical performance and comparison